Table 3.
Characteristics of included clinical trials (TCZ- Tocilizumab; STEMI- ST-segment elevation myocardial infarction; NSTEMI- Non ST-segment elevation myocardial infarction; M:F- Male: Female Ratio, hs-CRP- high sensitivity C-reactive protein, TnT- Cardiac Troponin-T).
| Trial | Source | Gender (M:F) |
Age, y mean (SD) or median (range) |
Patients | Population | Drug dose | Duration | Outcome measures | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Placebo | TCZ | Placebo | TCZ | |||||||
| NCT01491074 | Kleveland et al. 2016 [27] | 19:1 | 10:1 | 60.1 ± 9.9 | 59.8 ± 7.7 | NSTEMI | 117 | 280mg of TCZ/intravenously | 6 months | hs-CRP, hs-TnT, IL-6 levels, Serious adverse effects, Neutrophil count, cardiac function and Heart failure |
| NCT02419937 | Carroll et al. 2017 [28] | 14:2 | 10:2 | 67.7 ± 9.5 | 70.7 ± 10 | STEMI and NSTEMI | 28 | 162mg of TCZ/subcutaneously | 30 days | Major adverse cardiac events, CRP levels |
| NCT01491074 | Ueland et al. 2018 [29] | 19:1 | 10:1 | 60.1 ± 9.9 | 59.8 ± 7.7 | NSTEMI | 117 | 280mg of TCZ/intravenously | 6 months | Seum Lp(a) measurements |
| NCT01491074 | Orrem et al. 2018 [30] | 19:1 | 10:1 | 60.1 ± 9.9 | 59.8 ± 7.7 | NSTEMI | 117 | 280mg of TCZ/intravenously | 6 months | Expression of anaphylatoxin receptor, PBMC count |
| NCT01491074 | Kleveland et al. 2018 [31] | 19:1 | 10:1 | 60.1 ± 9.9 | 59.8 ± 7.7 | NSTEMI | 117 | 280mg of TCZ/intravenously | 6 months | Plasma levels of interferon gamma-inducible protein (IP-10) and macrophage inflammatory protein-1β |
| NCT01491074 | Holte et al. 2016 [32] | 0 female | 32:1 | 59.3 ± 9.5 | 57.8 ± 6.1 | NSTEMI | 42 | 280mg of TCZ/intravenously | 6 months | Coronary flow reserve measurements |
| NCT03004703 | Broch et al.2021 [33] | 4:1 | 62 ± 10 | 60 ± 9 | STEMI | 200 | 280mg of TCZ/intravenously | 6 months | Myocardial salvage index measured by cardiac MRI (CMR), include final infarct size measured by CMR and hs-CRP, hs-TnT levels. | |